CoChat

Extended interval BNT162b2 vaccination enhances peak antibody generation

Open access
Parry, Helen, Bruton, Rachel, Stephens, Christine, Bentley, Christopher, Brown, Kevin, Amirthalingam, Gayatri, Hallis, Bassam, Otter, Ashley, Zuo, Jianmin, Moss, Paul · 2022 · npj Vaccines

Published version of a preprint

Cited by 150

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

The BNT162b2 vaccine is highly effective against COVID-19 infection and was delivered with a 3-week time interval in registration studies 1 . However, many countries extended this interval to accelerate population coverage with a single vaccine. It is not known how immune responses are influenced by delaying the second dose. We provide the assessment of immune responses in the first 14 weeks after standard or extended-interval BNT162b2 vaccination and show that delaying the second dose strongly boosts the peak antibody response by 3.5-fold in older people. This enhanced antibody response may offer a longer period of clinical protection and delay the need for booster vaccination. In contrast, peak cellular-specific responses were the strongest in those vaccinated on a standard 3-week vaccine interval. As such, the timing of the second dose has a marked influence on the kinetics and magnitude of the adaptive immune response after mRNA vaccination in older people.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41541-022-00432-w

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 8

  1. Parry, H. M. et al. Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. Lancet Healthy Longev. 2, e554–e560 (2021). · DOI
  2. Bradley, T. et al. Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. https://doi.org/10.1056/NEJMc2102051 (2021). · DOI · Paper page
  3. Parry, H. M. et al. mRNA vaccination in people over 80 years of age induces strong humoral immune responses with cross neutralisation of P.1 Brazilian variant. Elife 10, e69375 (2021). · DOI · Paper page
  4. Perreault, J. et al. Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset. Blood 136, 2588–2591 (2020). · DOI · Paper page
  5. Walsh, E. E. et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N. Engl. J. Med. 383, 2439–2450 (2020). · doi:10.1056/nejmoa2027906 · Paper page
  6. Maue, A. C. et al. T-cell immunosenescence: lessons learned from mouse models of aging. Trends Immunol. 30, 301–305 (2009). · DOI · Paper page
  7. Pfizer. Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study, https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious (2021).
  8. Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, https://doi.org/10.1016/S0140-6736(21)00432-3 (2021). · DOI · Paper page

Cited by

See all 150

Metadata

Authors
Parry, H., Bruton, R., Stephens, C., Bentley, C., Brown, K., Amirthalingam, G., Hallis, B., Otter, A., Zuo, J., & Moss, P.
Venue
npj Vaccines
Published
2022-01-27
Volume
7
Issue
1
Pages
14-14
ISSN
2059-0105 (ISSN-L)
OpenAlex
W4210641662
Cited by
150
References
14
FWCI
11.79
Type
journal article
Language
en
Open access
gold
Licence
Funders
RCUK | Medical Research Council (MR/V028448/1, MC_PC_20031)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Extended interval BNT162b2 vaccination enhances peak antibody generation. https://app.cochat.ai/papers/10.1038/s41541-022-00432-w
The paper
Parry, H., Bruton, R., Stephens, C., Bentley, C., Brown, K., Amirthalingam, G., Hallis, B., Otter, A., Zuo, J., & Moss, P. (2022). Extended interval BNT162b2 vaccination enhances peak antibody generation. npj Vaccines. https://doi.org/10.1038/s41541-022-00432-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.